studies included a total of 941 consecutive patients, and 937 patients were evaluable for this analysis (Pedersen et al, 1987; Lassen et al, 1996) .
There were no limitations for inclusion into the studies with respect to PS, the presence of CNS or bone marrow metastases, liver function tests etc., resulting in a considerably higher fraction of patients with poor prognostic factors. Table 1 describes the study design of the two trials.
All data were stored in a database, and the association between treatment, pretreatment factors and early death was analysed with special reference to toxic deaths. The factors included stage, liver, bone marrow and brain metastases, gender, age, PS and biochemical and haematological variables. Pretreatment characteristics of ETD and ENTD patients were compared with the characteristics of those who survived the first 4 weeks (controls) to identify prognostic factors.
Statistical analysis
Data were analysed using an interactive program (SPSS, statistical package, 1995) . Patient characteristics were compared using χ 2 test for discrete data, and the KruskalÐWallis test for ordinal scale variables and continuous non-parametric data. Logistic regression analysis was used to analyse factors of prognostic significance for events such as early death, ENTD and ETD. In the analyses, LDH was categorized according to the multiplicity of upper normal levels (450 units l Ð1 ) and age was dichotomized to <65 or ³65 years. Survival analysis was calculated by the KaplanÐMeier method, and groups were compared for statistically significant difference using the log-rank method.
RESULTS

Treatment comparison
The frequencies of ED and ETD were less than 3.4% and 1.4%, respectively, in our trials performed in 1976Ð81 (¯sterlind et al, 1983, 1986, 1991) . In a later randomized trial, these figures changed in a treatment arm with early inclusion of etoposide, based on in vivo cell cyclus analysis. In this arm, ED and ETD were encountered in 19% and 10%, respectively, and grade IV leucopenia was observed in 51% of the patients (Hirsch et al, 1987) . Table 2 shows the distribution of grade IV leucopenia, median white blood cell (WBC) nadir, ENTD and ETD in the different treatment regimens of the trials. The combination of epipodophyllotoxins and platinum (EP) in the induction regimens resulted in an increased number of toxic deaths (P = 0.0002), whereas treatment had no significant impact on ENTD. The sequential arm in the first trial was more myelotoxic than the other treatment arms (median WBC nadir 760 mm Ð3 , P < 0.001). In the latest trial, ETD was more frequently observed in the EP regimens even though low median WBC nadir and grade IV leucopenia were more pronounced in the non-EP regimens. The duration of the leucopenic episodes have not been recorded. In general, significantly more ETD occurred among patients receiving EP (P = 0.04).
When early death patients were excluded from the two trials, the outcome was significantly changed. In the 1981Ð85 trial, the survival inferiority of the EP regimens disappeared and no survival difference was present (P = 0.15). In the 1985Ð91 trial, the significant superiority (P = 0.04) of the EP regimens increased (P = 0.002), as reflected by a difference in median survival of 2 months compared with the previous 1 month. Figure 1 compares the survival curves of all patients, early deaths and the patients surviving the first 4 weeks of treatment. 
Prognostic factors
A total of 941 patients were included in the two trials from 1981 to 1991, and 932 patients were evaluable for the analysis of prognostic factors. One hundred and eighteen patients died during the first 4 weeks after start of treatment (12.6%). The most frequent cause of death was disease progression, but whether a patient died from progression or concurrent diseases could not always be defined because some patients died at home and because autopsy was not performed routinely. A majority of ED occurred during the second week after initiation of chemotherapy when blood cell counts were at the lowest level, and ETD was recorded in 38 patients (4%). In some instances, ED may have been caused by a combination of toxicity, progression or concurrent diseases. Table  3 shows the pretreatment characteristics of ENTD patients, ETD patients and the control group. Extensive disease and elevated liver enzymes were significantly more frequent among patients who died within the first 4 weeks, whereas the sex ratio was equal between the groups. Also, poor PS was more frequently observed in early deaths. However, 27% of ETD had initial PS 1 and 27% had initial PS 2. The median age and the median values of lactate dehydrogenase (LDH) and alkaline phosphatase (AP) were significantly higher in patients dying early (KruskalÐWallis). These factors were equally distributed between the ENTD and ETD group, except extensive stage which was less frequently observed with ETD (P = 0.05, χ 2 test). A variable indicating induction regimens containing epipodophyllotoxins and platinum was introduced (EP). This variable was added to the statistically significant variables from the univariate analysis in subsequent logistic regression analyses of factors with prognostic impact on early death, ETD and ENTD (Table 4 ). Significant risk factors of early death were high age, poor performance status, elevated LDH and EP treatment. High age, poor performance status and elevated LDH were statistically significant risk factors for ENTD. Extensive stage of disease resulted in a hazard ratio of 1.9, but the confidence interval did not reach significance (P = 0.07). EP had no influence on ENTD, and age was not a significant factor in a separate analysis of limited disease only. The same analysis of ETD showed that poor PS and elevated LDH were statistically significant. EP was a powerful factor of ETD with a hazard ratio of 6.7. Neither bone marrow nor liver or brain metastases were independent predictive factors for early death or early toxic death. The patients with PS 1 or 2 had significantly increased hazard ratios for elevated LDH, age ³65 and EP regimens (hazard ratios 1.7, 2.4 and 5.3 respectively). Based on hazards from the analyses of both ENTD and ETD, a prognostic algorithm for early death was introduced. The major prognostic factors were weighted according to the hazard. PS 3 or 4 scored 2 points, LDH > twice upper normal level and age >65 years each scored 1 point. Stage was not a significant prognostic factor for ED and was not included in the algorithm. Patients were allocated to the poor prognosis group if the total score was 2 points or more (Table 5 ). The poor prognosis group included patients with PS 3 or 4 or LDH > twice upper normal level and age ³65. With this algorithm, a majority of EDs could be excluded; this group accounted for 21% of the patients. The remaining 79% of the patients were allocated to a favourable prognosis group and a survival analysis was performed. In the trial from 1981 to 1985, the inferiority of the EP regimen was reduced after exclusion of the majority of early deaths, but it was still significant (P = 0.03).
In the 1985Ð91 trial, the superiority of EP compared with non-EP regimens became more pronounced when the analysis only included the favourable prognosis patients (median survival 376 days vs 310 days respectively, P = 0.03). In the favourable group, 3-year survival was 11.4% compared with 7.8% among all patients receiving EP. These changes were comparable to the changes resulting when early deaths were excluded from the survival analyses. Figure 2 compares the survival curves for all patients, the favourable and the poor prognosis groups. In the poor prognosis group, median survival was 133 days, and 2-and 3-year survival rates were 4.5% and 2.0% respectively. In this group of patients, the frequency of early death was 33%, and among the patients receiving EP the frequency was 41%.
DISCUSSION
Previous studies of early death have identified stage, PS and liver enzymes as significant prognostic factors, but also epipodophyllotoxins have been proposed to be responsible for an increased risk of early toxic death (Morittu et al, 1989) . It has been suggested that this possibly could be caused by an association between hepatic metastases, compromised liver function and elimination of etoposide (Pfluger et al, 1987; Morittu et al, 1989) . However, a discrimination between early death due to progression and early death due to infection was not made in these studies. Other studies have focused on toxic death alone. Radford et al (1993) identified factors predicting septic complications in an analysis of 382 patients and derived a prognostic index including PS ³3, age >50 and three or more drugs. However, the Radford et al (1993) study did not discriminate between early or later toxicity. Another large analysis of 2196 patients modified the Radford index by omitting age and including WBC ³10 000 mm Ð3 . In addition, PS was modified to ³2 and the number of drugs increased to four or more. Patients dying from sepsis were not recorded and the analysis was exclusively based on excess death rates during the first treatment cycle (Stephens et al, 1994) .
The fact that ETD was more frequent in the EP regimens in our latest trial despite the fact that leucopenia was more pronounced in the control regimen indicates the complexity of this problem. The schedule of administration of epipodophyllotoxins has previously been shown to be important for outcome. Based on in vivo cell kinetic observations, it has been shown that etoposide has maximal activity against cells in the S and G 2 phases (Kalwinsky et al, 1983) . In most regimens, epipodophyllotoxins, therefore, are administered for 3Ð5 days early in each cycle. This was also the case in our regimens. This could possibly result in nadir periods of longer duration compared with regimens in which the drugs are administered in 1 day. Unfortunately, our haematological surveillance did not include daily blood cell counts. This was only the case when grade IV toxicity had resulted in hospitalization of the patients. Therefore, a comparison of nadir durations among the different regimens could not be performed.
Risk of early death due to infection seems to be more independent of stage, and fatal toxicity occurred in both stages. Increased LDH was an independent prognostic factor, presumably related to tumour burden rather than to hepatic function. PS was found to be the most powerful risk factor of both toxic and non-toxic early death. Stratification for PS and LDH is extremely important in both disease stages because these patients have an increased risk of early toxic death when treated with extraordinary myelotoxic combination chemotherapy. It is noteworthy that more than 50% of ETD occurred among patients with PS 1 or 2. A majority of these patients had increased LDH and were more than 65 years old. Therefore, it is difficult to propose a simple algorithm predicting risk of ETD. Patients with PS 1 in general have a favourable prognosis and should be included in clinical trials. Our data suggest that good performance patients should receive increased haematological surveillance if they are more than 65 years old or have elevated LDH. In addition, treatment with colony-stimulating factors could possibly reduce the risk of ETD in this group, but this needs further evaluation in prospective clinical trials. If the patients are older than or equal to 65 years and have moderately elevated LDH, they should be excluded from trials with potent myelosuppressive agents.
Most phase II and III trials of high-dose chemotherapy and dose intensification have been disappointing with regard to survival (Stahel et al, 1984; Johnson et al, 1987; Jackson et al, 1988; Klasa et al, 1991; Katakami et al, 1996; Fetscher et al, 1997; Murray et al, 1997) . Most of these trials only included patients with good performance status and thereby excluded approximately 15% of the patients. If patients with other poor prognostic factors had been excluded, the results might have been in favour of treatment intensification. Epipodophyllotoxins can safety be administered to elderly patients (Bork et al, 1991 (Bork et al, , 1997 . The risk of toxic death is correlated to dose intensity and scheduling with other agents. According to this and other similar analyses, the goal for treatment of patients with poor prognosis primarily is palliative. It should not be too intensive (Girling et al, 1996a) , albeit monotherapy with etoposide may be suboptimal (Girling et al, 1996b; Souhami et al, 1997) compared with intravenous combination chemotherapy. Our analysis did not address how to treat such patients; epipodophyllotoxins and platinum are widely used, and dosage and scheduling will always depend on a narrow balance between efficacy and toxicity.
Our algorithm included predictive factors for both ENTD and ETD. The frequency of early death among the excluded group of patients was as high as 41% when receiving EP. We propose that other groups use and evaluate our algorithm to exclude patients with poor prognosis from regimens with potent myelosuppressive agents and trials with dose intensification or dose escalation. Exclusion of such patients may reveal that dose intensification will result in a significantly improved outcome. This should encourage further randomized studies in SCLC in patients with a favourable prognosis. These account for approximately 80% of the patients who better tolerate intensive treatment, and an increased toxicity is acceptable provided more patients become long-term survivors.
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